Business

Eurofins Delivers FY 2025 Objectives with a 24% EPS Growth, Accelerating Organic Revenue Growth, Margin Expansion, and Higher Free Cash Flow and Confirms Its 2027 Objectives

LUXEMBOURG, January 29, 2026--Regulatory News: Eurofins (Paris:ERF) pre-publishes below its preliminary unaudited consolidated financial results for the year ending 31 December 2025, as described in the first paragraphA of the Business Review section of this press release.

articleEurofins Scientific SeJanuary 29, 202655/company/eurofins-scientific-se-1/news/eurofins-delivers-fy-2025-objectives-with-a-24percent-eps-growth-accelerating-organic-revenue-growth-margin-expansion-and-higher-free-cash-flow-and-confirms-its-2027-objectives-1
Eurofins Delivers FY 2025 Objectives with a 24% EPS Growth, Accelerating Organic Revenue Growth, Margin Expansion, and Higher Free Cash Flow and Confirms Its 2027 Objectives

About this update from Eurofins Scientific Se

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1518,"height":299,"url":"https://media.zenfs.com/en/business-wire.com/d7b76e5abf4aad4cd6ccd798fb1e3228"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tXtBnl1HghR9VrGzVCVKgw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE4OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d7b76e5abf4aad4cd6ccd798fb1e3228","width":960,"height":189},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/9xH7inFnA89rI_E4k7XFDA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NzI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/d7b76e5abf4aad4cd6ccd798fb1e3228","width":1200,"height":236}},"lazy":false},{"type":"text","content":"LUXEMBOURG, January 29, 2026--(BUSINESS WIRE)--Regulatory News:","length":63,"tagName":"p"},{"type":"text","content":"Eurofins (Paris:ERF) pre-publishes below its preliminary unaudited consolidated financial results for the year ending 31 December 2025, as described in the first paragraphA of the Business Review section of this press release.","length":231,"tagName":"p"},{"type":"text","content":"Financial highlights in FY 2025","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Basic EPS8 grew 24% to €2.31 in 2025 vs €1.87 in 2024, driven by a strong operating performance and starting to reap the benefits from Eurofins five-year investment programme in its hub and spoke network and digitalization initiatives. Basic EPS8 growth accelerated in H2 2025, and reached 30%.","length":294,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Revenues of €7,296m increased by 5.0% as reported, and 4.1% organically13 including an adjustment for public working days of +0.4%. Organic growth13 strengthened as the year progressed, with the highest growth rate observed in Q4.","length":230,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The Adjusted1 EBITDA3 margin18 reached 24.3% on Mature scope14 revenues in 2025, ahead of Eurofins’ mid-term objective for the Group. Adjusted1 EBITDA3 achieved €1,641m in 2025, an expansion of Adjusted1 EBITDA3 margin18 to 22.5% of total reported revenues. This improvement was achieved in spite of headwinds from currency translation and the initial dilution from the revenues resulting from the acquisition of Synlab’s...

More updates from Eurofins Scientific Se

EurofinsFYFree Cash FlowEurofinsintangible assetsNorth AmericaNorth America